Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 2.82
ACRX's Cash-to-Debt is ranked higher than
50% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.87 vs. ACRX: 2.82 )
Ranked among companies with meaningful Cash-to-Debt only.
ACRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.31  Med: 3.42 Max: 9.07
Current: 2.82
0.31
9.07
Equity-to-Asset -0.40
ACRX's Equity-to-Asset is ranked lower than
96% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ACRX: -0.40 )
Ranked among companies with meaningful Equity-to-Asset only.
ACRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.4  Med: 0.41 Max: 0.69
Current: -0.4
-0.4
0.69
Debt-to-Equity -0.70
ACRX's Debt-to-Equity is ranked lower than
99.99% of the 215 Companies
in the Global Medical Devices industry.

( Industry Median: 0.27 vs. ACRX: -0.70 )
Ranked among companies with meaningful Debt-to-Equity only.
ACRX' s Debt-to-Equity Range Over the Past 10 Years
Min: -54.07  Med: 0.46 Max: 6.52
Current: -0.7
-54.07
6.52
Debt-to-EBITDA -0.64
ACRX's Debt-to-EBITDA is ranked lower than
99.99% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. ACRX: -0.64 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ACRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.37  Med: -0.83 Max: -0.53
Current: -0.64
-2.37
-0.53
Piotroski F-Score: 1
Altman Z-Score: -4.96
Beneish M-Score: -2.18
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -238.47
ACRX's Operating Margin % is ranked lower than
83% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. ACRX: -238.47 )
Ranked among companies with meaningful Operating Margin % only.
ACRX' s Operating Margin % Range Over the Past 10 Years
Min: -1805.22  Med: -452.89 Max: -22.6
Current: -238.47
-1805.22
-22.6
Net Margin % -319.19
ACRX's Net Margin % is ranked lower than
85% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. ACRX: -319.19 )
Ranked among companies with meaningful Net Margin % only.
ACRX' s Net Margin % Range Over the Past 10 Years
Min: -1875.09  Med: -443.98 Max: -79.4
Current: -319.19
-1875.09
-79.4
ROA % -51.10
ACRX's ROA % is ranked lower than
81% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.11 vs. ACRX: -51.10 )
Ranked among companies with meaningful ROA % only.
ACRX' s ROA % Range Over the Past 10 Years
Min: -134.55  Med: -63.33 Max: -22.78
Current: -51.1
-134.55
-22.78
ROC (Joel Greenblatt) % -364.32
ACRX's ROC (Joel Greenblatt) % is ranked lower than
80% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.41 vs. ACRX: -364.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1434.7  Med: -878.27 Max: -173.98
Current: -364.32
-1434.7
-173.98
3-Year Revenue Growth Rate -19.80
ACRX's 3-Year Revenue Growth Rate is ranked lower than
85% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. ACRX: -19.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -9.9 Max: 58.9
Current: -19.8
0
58.9
3-Year EBITDA Growth Rate 61.10
ACRX's 3-Year EBITDA Growth Rate is ranked higher than
91% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ACRX: 61.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50.2 Max: 61.1
Current: 61.1
0
61.1
3-Year EPS without NRI Growth Rate 17.20
ACRX's 3-Year EPS without NRI Growth Rate is ranked higher than
68% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. ACRX: 17.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -45.7 Max: 17.2
Current: 17.2
0
17.2
» ACRX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ACRX Guru Trades in Q2 2015

Paul Tudor Jones 24,100 sh (-54.18%)
» More
Q3 2015

ACRX Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
» More
Q2 2016

ACRX Guru Trades in Q2 2016

Jim Simons 21,100 sh (New)
» More
Q3 2016

ACRX Guru Trades in Q3 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3829
Compare:TPE:4104, ROCO:4107, NAS:FONR, ASX:SOM, XKRX:085370, ASX:OSP, ROCO:4129, NAS:OBLN, XTER:EUZ, NAS:CGNT, ROCO:4736, OSL:MEDI, ROCO:4126, XTER:MF6, TSE:7703, ASX:IPD, TSE:3079, NAS:NVTR, ASX:RVA, XKRX:228850 » details
Traded in other countries:R5X.Germany,
Headquarter Location:USA
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of therapies for the treatment of acute pain.

AcelRx Pharmaceuticals Inc was was incorporated in Delaware on July 13, 2005 as SuRx, Inc. In January 2006, the Company has changed its name to AcelRx Pharmaceuticals, Inc. It is a development stage company. The Company is a specialty pharmaceutical company engaged in the development and commercialization of therapies for the treatment of acute and breakthrough pain. Its product candidate, DSUVIA (known as ARX-04 outside of the United States), and follow-on product candidate, ZALVISO, utilize sublingual sufentanil, delivered via a non-invasive route of administration.

Top Ranked Articles about AcelRx Pharmaceuticals Inc

AcelRx's DSUVIA™ Clinical Trial Results Selected as a "Top Abstract" for Oral Presentation at ASA's Annual Meeting - ANESTHESIOLOGY® 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. - ACRX
CarGurus Gains Nearly 80% in 1st Day of Trading AcelRx, Blackhawk Network and Juniper Networks fall
On Thursday, the U.S. stock market closed lower, falling from yesterday's record highs. Read more...
AcelRx Pharmaceuticals Receives Complete Response Letter from the FDA for DSUVIA™ NDA
AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September
AcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
AcelRx Pharmaceuticals to Hold a Conference Call and Webcast on Tuesday, August 1st to Discuss ZALVISO Phase 3 Top-line Data and Quarterly Financial Results
AcelRx Pharmaceuticals to Hold Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2nd
AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer
Wall Street Opens With Mixed Results Ahead of BlackRock Results and China's Expansion BlackRock dissapoints investors
The markets are trading in mixed territory after U.S. stock market hit record highs on Friday, and futures are indicating stocks could go up more today. Read more...

Ratios

vs
industry
vs
history
PS Ratio 5.81
ACRX's PS Ratio is ranked lower than
85% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. ACRX: 5.81 )
Ranked among companies with meaningful PS Ratio only.
ACRX' s PS Ratio Range Over the Past 10 Years
Min: 4.69  Med: 25.16 Max: 2370
Current: 5.81
4.69
2370
EV-to-EBIT -1.38
ACRX's EV-to-EBIT is ranked lower than
99.99% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 23.37 vs. ACRX: -1.38 )
Ranked among companies with meaningful EV-to-EBIT only.
ACRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -158.7  Med: -3.15 Max: 107.8
Current: -1.38
-158.7
107.8
EV-to-EBITDA -1.46
ACRX's EV-to-EBITDA is ranked lower than
99.99% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 17.75 vs. ACRX: -1.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -201.3  Med: -3.3 Max: 93.6
Current: -1.46
-201.3
93.6
EV-to-Revenue 3.25
ACRX's EV-to-Revenue is ranked lower than
79% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. ACRX: 3.25 )
Ranked among companies with meaningful EV-to-Revenue only.
ACRX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 19.6 Max: 1569.2
Current: 3.25
1.6
1569.2
Current Ratio 4.92
ACRX's Current Ratio is ranked higher than
81% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. ACRX: 4.92 )
Ranked among companies with meaningful Current Ratio only.
ACRX' s Current Ratio Range Over the Past 10 Years
Min: 0.43  Med: 5.29 Max: 20.39
Current: 4.92
0.43
20.39
Quick Ratio 4.81
ACRX's Quick Ratio is ranked higher than
85% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ACRX: 4.81 )
Ranked among companies with meaningful Quick Ratio only.
ACRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.43  Med: 5.26 Max: 20.39
Current: 4.81
0.43
20.39
Days Inventory 45.18
ACRX's Days Inventory is ranked higher than
88% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 139.39 vs. ACRX: 45.18 )
Ranked among companies with meaningful Days Inventory only.
ACRX' s Days Inventory Range Over the Past 10 Years
Min: 38.83  Med: 43.44 Max: 48.05
Current: 45.18
38.83
48.05
Days Sales Outstanding 48.53
ACRX's Days Sales Outstanding is ranked higher than
81% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 67.97 vs. ACRX: 48.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.53  Med: 92.46 Max: 122.66
Current: 48.53
48.53
122.66
Days Payable 27.98
ACRX's Days Payable is ranked lower than
81% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. ACRX: 27.98 )
Ranked among companies with meaningful Days Payable only.
ACRX' s Days Payable Range Over the Past 10 Years
Min: 27.98  Med: 184.04 Max: 321.9
Current: 27.98
27.98
321.9

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.70
ACRX's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: -4.90 vs. ACRX: -1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -303.2  Med: -18.8 Max: 0
Current: -1.7
-303.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.23
ACRX's Price-to-Median-PS-Value is ranked higher than
87% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. ACRX: 0.23 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 1.05 Max: 91.8
Current: 0.23
0.2
91.8
Earnings Yield (Greenblatt) % -72.46
ACRX's Earnings Yield (Greenblatt) % is ranked lower than
83% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.94 vs. ACRX: -72.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -93.2  Med: -26.5 Max: 9.1
Current: -72.46
-93.2
9.1

More Statistics

Revenue (TTM) (Mil) $15.57
EPS (TTM) $ -1.09
Beta3.14
Short Percentage of Float17.20%
52-Week Range $1.55 - 5.75
Shares Outstanding (Mil)45.38

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 13 29 69 124
EPS ($) -1.14 -0.92 -0.17 0.42
EPS without NRI ($) -1.14 -0.92 -0.17 0.42
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 11
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}